Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 7:21 PM
Ignite Modification Date: 2025-12-24 @ 7:21 PM
NCT ID: NCT04542603
Eligibility Criteria: Inclusion Criteria: 1. 50 years of age or older 2. Female gender 3. Newly diagnosed treatment naïve women with stage III/IV epithelial ovarian cancer (without known brain metastases). 4. High or mixed affinity binder for TSPO ligands based on genotyping for single nucleotide polymorphism (SNP) rs6971. 5. English is primary language 6. Planned neoadjuvant chemotherapy with platinum and taxane drugs Exclusion Criteria: 1. Contraindication to MRI 2. Pregnancy 3. Lactation 4. Individuals who are unable to participate in the imaging portion due to severity of their medical condition 5. Chronic infectious disease (e.g. HIV, HCV) 6. Chronic inflammatory disease (e.g., fibromyalgia, MS, etc) or autoimmune disease 7. Viral or bacterial illness requiring medical attention and/or antibiotics within 1 month of study participation 8. Blood or blood clotting disorder 9. Cancer that has metastasized to the brain 10. Positive urine hCG test day of procedure or a serum hCG test within 48 hours prior to the administration of \[18F\]DPA-714 and \[11C\]PiB. 11. Currently enrolled in a clinical trial utilizing experimental therapies. 12. Low affinity binder for TSPO ligands based on genotyping for SNP rs6971. 13. Prior brain tumor or other neurological condition known to affect cognition 14. A diagnosis of dementia unrelated to cancer or an adjusted MMSE score \< 24
Healthy Volunteers: False
Sex: FEMALE
Minimum Age: 50 Years
Study: NCT04542603
Study Brief:
Protocol Section: NCT04542603